• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Optimization of immunotherapy for patients with hepatobiliary cancer.肝胆癌患者免疫治疗的优化
Hepatobiliary Surg Nutr. 2021 Oct;10(5):717-719. doi: 10.21037/hbsn-21-207.
2
Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status.美国肝胆癌免疫疗法的应用：不同社会经济地位患者之间的差异
Hepatobiliary Surg Nutr. 2020 Feb;9(1):13-24. doi: 10.21037/hbsn.2019.07.01.
3
The State of Immunotherapy in Hepatobiliary Cancers.免疫疗法在肝胆肿瘤中的应用现状
Cells. 2021 Aug 15;10(8):2096. doi: 10.3390/cells10082096.
4
Treating Hepatobiliary Cancer: The Immunologic Approach.治疗肝胆癌：免疫治疗方法。
Dig Dis. 2017;35(4):390-396. doi: 10.1159/000456593. Epub 2017 May 3.
5
Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer.树突状细胞疫苗联合细胞因子诱导的杀伤细胞疗法治疗肝胆胰癌的临床疗效
Mol Clin Oncol. 2016 Jan;4(1):129-133. doi: 10.3892/mco.2015.660. Epub 2015 Oct 23.
6
Novel immunotherapy strategies for hepatobiliary cancers.新型免疫疗法治疗肝胆肿瘤。
Immunotherapy. 2018 Sep;10(12):1077-1091. doi: 10.2217/imt-2018-0024.
7
The microbiome and hepatobiliary-pancreatic cancers.微生物组与肝胆胰癌症
Cancer Lett. 2017 Aug 28;402:9-15. doi: 10.1016/j.canlet.2017.05.001. Epub 2017 May 17.
8
Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.肝胆胰肿瘤的癌症疫苗和免疫治疗方法。
Hum Vaccin Immunother. 2017 Dec 2;13(12):2931-2952. doi: 10.1080/21645515.2017.1359362. Epub 2017 Nov 7.
9
T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy.T 细胞亚群作为肝胆癌的潜在生物标志物，以及免疫治疗方案作为治疗策略的选择。
J Natl Compr Canc Netw. 2022 Feb;20(2):203-214. doi: 10.6004/jnccn.2021.7097.
10
Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid.3.0T 场强下优化的高分辨率肝胆特异性对比剂磁共振成像：钆贝葡胺与钆塞酸二钠的交叉比较。
J Magn Reson Imaging. 2011 Sep;34(3):585-94. doi: 10.1002/jmri.22713. Epub 2011 Jul 12.

引用本文的文献

1
Liver transplantation for cholangiocarcinoma: exploring a new land.胆管癌的肝移植：探索新领域。
J Gastrointest Oncol. 2022 Oct;13(5):2696-2698. doi: 10.21037/jgo-22-596.
2
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance.肿瘤微环境异质性是前列腺癌进展和治疗抵抗的重要介导因素。
NPJ Precis Oncol. 2022 May 4;6(1):31. doi: 10.1038/s41698-022-00272-w.

本文引用的文献

1
Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.肿瘤相关巨噬细胞中程序性死亡配体 1 蛋白的优先表达及其在肝癌免疫治疗中的潜在作用。
Int J Mol Sci. 2021 Apr 29;22(9):4710. doi: 10.3390/ijms22094710.
2
Synergistic effects of anti-angiogenesis and immune checkpoint blockade - a new era of systemic chemotherapy for hepatocellular carcinoma.抗血管生成与免疫检查点阻断的协同效应——肝细胞癌全身化疗的新时代。
Hepatobiliary Pancreat Dis Int. 2021 Oct;20(5):493-495. doi: 10.1016/j.hbpd.2021.04.004. Epub 2021 Apr 16.
3
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.NASH 限制了免疫治疗治疗 HCC 的肿瘤监测。
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.
4
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma.肝细胞癌中对PD-1抑制有反应和无反应患者的临床和遗传肿瘤特征
Cancers (Basel). 2020 Dec 18;12(12):3830. doi: 10.3390/cancers12123830.
5
Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma.通过靶向二代测序对肿瘤突变负荷进行鉴定作为肝细胞癌的生物标志物
Liver Int. 2021 Jan;41(1):192-203. doi: 10.1111/liv.14706. Epub 2020 Nov 16.
6
Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.免疫检查点抑制剂治疗胃肠道、肝胆和胰腺癌的现状
Therap Adv Gastroenterol. 2020 Aug 21;13:1756284820948773. doi: 10.1177/1756284820948773. eCollection 2020.
7
Recent Advances in Immunotherapy for Hepatocellular Carcinoma.肝细胞癌免疫治疗的最新进展
Cancers (Basel). 2020 Mar 25;12(4):775. doi: 10.3390/cancers12040775.
8
Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status.美国肝胆癌免疫疗法的应用：不同社会经济地位患者之间的差异
Hepatobiliary Surg Nutr. 2020 Feb;9(1):13-24. doi: 10.21037/hbsn.2019.07.01.
9
Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.微卫星不稳定性与免疫检查点抑制剂：迈向胃肠道和肝胆癌症的精准医学。
J Gastroenterol. 2020 Jan;55(1):15-26. doi: 10.1007/s00535-019-01620-7. Epub 2019 Sep 7.
10
Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.晚期肝细胞癌中已确立和新出现的免疫检查点抑制剂反应生物标志物的患病率
Oncotarget. 2019 Jun 18;10(40):4018-4025. doi: 10.18632/oncotarget.26998.

Optimization of immunotherapy for patients with hepatobiliary cancer.

作者信息

Eso Yuji, Seno Hiroshi

机构信息

Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

Hepatobiliary Surg Nutr. 2021 Oct;10(5):717-719. doi: 10.21037/hbsn-21-207.

DOI:10.21037/hbsn-21-207
PMID:34760984
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8527416/
Abstract
摘要